Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible to participate in this study: * Age 18-75 years at the time of the screening visit * Able to provide informed consent and comply with study procedures * Sporadic ALS diagnosed as probable, laboratory-supported probable or definite according to the World Federation of Neurology El Escorial revised criteria as determined by a neurologist with neuromuscular sub-specialty training * Diagnosis \<24 months from date of enrolment * (Forced) Vital capacity at least 60% of predicted value for gender, height and age at the screening visit * Must be on a stable dose of riluzole for at least 30 days prior to the screening visit. * Subject has established care with a neurologist at one of the four specialized ALS clinics involved in the study and will maintain this clinical care throughout the study. * Subjects can participate in clinical registries, but will be excluded to this protocol if they are participating in a clinical trial involving additional or investigative treatment exposure. Exclusion Criteria: A participant will be excluded if he or she has any of the following: * Dependence on mechanical ventilation at the time of screening * Gastrostomy at the time of screening * Absence of Upper Motor Neuron Signs * Participation in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening) * Known hypersensitivity to dolutegravir, abacavir or lamivudine, or to any of the excipients * Presence of the HLA-B\*5701 allele at screening * Presence of a monogenic cause of ALS (e.g. known mutation in SOD1, expansion in c9orf72 etc.) * History of positive test or positive result at screening for HIV * Subjects positive for Hepatitis B at screening (+HBsAg), or anticipated need for Hepatitis C virus (HCV) therapy during the study\*; * Women must not be able to become pregnant (post menopausal for \>1 year, surgically sterile, adequate contraception) or breastfeed for the duration of the study. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating * Other interventional clinical trial * Subject is taking medication contraindicated with Triumeq. Dofetilide (or pilsicainide \[available in Japan\]) is prohibited as DTG may inhibit its renal tubular secretion resulting in increased dofetilide concentrations and potential for toxicity. * Presence of any of the following clinical conditions at the time of screening: Drug or alcohol abuse Unstable medical disease (such as unstable angina or chronic obstructive pulmonary disease), or active infectious disease (such as Hepatitis B or C or tuberculosis), or current malignancy Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit. This exclusion criteria is based on a prior psychiatric diagnosis that is unstable as determined by the subject's treating Psychiatrist Dementia as previously diagnosed by a medical practitioner • Safety Laboratory Criteria at the screening visit: Alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN), OR ALT \>3xULN Total bilirubin, lactate, triglycerides, amylase, or lipase greater than 2.0 times the upper limit of normal Subject has creatinine clearance of \<50 mL/min via Cockroft-Gault method Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification; Absolute neutrophil count of \< 1 x 109/L Platelet concentration of \< 100 x 109/L Haemoglobin \< 100g/L